The Protocol Review and Monitoring System (PRMS), under the leadership of Michael Bookman M.D., has been substantially modified in response to the critique of the previous site review. The PRMS includes the Research Review Committee (RRC), which provides the primary mechanisms for scientific evaluation of new and ongoing clinical research protocols, and has the authority to activate and close all clinical studies in conjunction with the Institutional Review Board (IRB). Administrative support is coordinated through another element of PRMS, the Protocol Management Office, which facilitates staff assignments, broad consideration of resource utilization and protocol staff review of operational details for each new study. The PRMS reports directly to the Senior Vice President for Medical Science, Dr. Ozols. During the last granting period, significant changes have occurred, including: a) the development of standardized forms for submission and review of protocols; b) increased written communication with the IRB; c) expanded collection of accrual data in a centralized relational database; d) mandatory annual scientific review of all active studies; e) automated generation of protocol-specific annual review materials; review of all protocol amendments; and f) early involvement of biostatisticians in protocol design and approval, prior to presentation at RRC. The PRMS underwent an additional peer review in 1996, consequent upon recommendations of the previous full site review, and was approved.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA006927-40
Application #
6652222
Study Section
Subcommittee G - Education (NCI)
Project Start
2002-07-01
Project End
2003-06-30
Budget Start
1998-10-01
Budget End
1999-09-30
Support Year
40
Fiscal Year
2002
Total Cost
$196,218
Indirect Cost
Name
Fox Chase Cancer Center
Department
Type
DUNS #
042250712
City
Philadelphia
State
PA
Country
United States
Zip Code
19111
Gabbasov, Rashid; Xiao, Fang; Howe, Caitlin G et al. (2018) NEDD9 promotes oncogenic signaling, a stem/mesenchymal gene signature, and aggressive ovarian cancer growth in mice. Oncogene 37:4854-4870
Nacson, Joseph; Krais, John J; Bernhardy, Andrea J et al. (2018) BRCA1 Mutation-Specific Responses to 53BP1 Loss-Induced Homologous Recombination and PARP Inhibitor Resistance. Cell Rep 24:3513-3527.e7
Fahl, Shawn P; Coffey, Francis; Kain, Lisa et al. (2018) Role of a selecting ligand in shaping the murine ??-TCR repertoire. Proc Natl Acad Sci U S A 115:1889-1894
Jones, Caitlin E; Hammer, Anisha M; Cho, YouJin et al. (2018) Stromal PTEN Regulates Extracellular Matrix Organization in the Mammary Gland. Neoplasia 21:132-145
Shaikh, Talha; Wang, Lora S; Egleston, Brian et al. (2018) Predictors of Hematologic Toxicity and Chemotherapy Dose Intensity in Patients Undergoing Chemoradiation for Pancreatic Cancer. Am J Clin Oncol 41:59-64
Campbell, Kerry S; Cohen, Adam D; Pazina, Tatiana (2018) Mechanisms of NK Cell Activation and Clinical Activity of the Therapeutic SLAMF7 Antibody, Elotuzumab in Multiple Myeloma. Front Immunol 9:2551
Blackman, Elizabeth; Ashing, Kimlin; Gibbs, Denise et al. (2018) The Cancer Prevention Project of Philadelphia: preliminary findings examining diversity among the African diaspora. Ethn Health :1-17
Fatkhullina, Aliia R; Peshkova, Iuliia O; Dzutsev, Amiran et al. (2018) An Interleukin-23-Interleukin-22 Axis Regulates Intestinal Microbial Homeostasis to Protect from Diet-Induced Atherosclerosis. Immunity 49:943-957.e9
Gupta, Sapna; Kelow, Simon; Wang, Liqun et al. (2018) Mouse modeling and structural analysis of the p.G307S mutation in human cystathionine ?-synthase (CBS) reveal effects on CBS activity but not stability. J Biol Chem 293:13921-13931
Sementino, Eleonora; Menges, Craig W; Kadariya, Yuwaraj et al. (2018) Inactivation of Tp53 and Pten drives rapid development of pleural and peritoneal malignant mesotheliomas. J Cell Physiol 233:8952-8961

Showing the most recent 10 out of 1280 publications